يعرض 1 - 20 نتائج من 89 نتيجة بحث عن '"Toldbod, Helle"', وقت الاستعلام: 0.53s تنقيح النتائج
  1. 1
    Conference

    المصدر: Relander , T , Leivonen , S , Larsen , T S , Brown , P D N , Jørgensen , J M , Mannisto , S , Lugtenburg , P J , Holte , H , Fagerli , U-M , Lauritzsen , G F , Meyer , P , Liestøl , K , Toldbod , H , Leppä , S & d'Amore , F A 2023 , ' LONG-TERM FOLLOW-UP AND GENE EXPRESSION PROFILES ASSOCIATED WITH OUTCOME IN PATIENTS WITH RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS TREATED IN THE NORDIC P[R]EBEN TRIAL ' , Hematological Oncology , vol. ....

  2. 2
    Academic Journal

    المساهمون: Hematologian yksikkö, Clinicum, Department of Oncology, HUS Comprehensive Cancer Center

    وصف الملف: application/pdf

    Relation: Janssen and Celgene.; Jerkeman , M , Eskelund , C W , Hutchings , M , Räty , R , Wader , K F , Laurell , A , Toldbod , H , Pedersen , L B , Niemann , C U , Dahl , C , Kuitunen , H , Geisler , C H , Gronbaek , K & Kolstad , A 2018 , ' Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON) : a multicentre, open-label, single-arm, phase 2 trial ' , The lancet. Haematology , vol. 5 , no. 3 , pp. E109-E116 . https://doi.org/10.1016/S2352-3026(18)30019-X; http://hdl.handle.net/10138/300987; ff66c3e0-3053-49a8-a636-49e92595d876; 85041169342; 000426417700006

  3. 3
    Academic Journal
  4. 4
    Conference
  5. 5
  6. 6
  7. 7
    Academic Journal
  8. 8
    Conference

    المصدر: Leivonen , S-K , Larsen , T S , Pasanen , A , Karjalainen-Lindsberg , M-L , Toldbod , H M , d'Amore , F A & Leppä , S 2019 , ' Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study ' , Blood , vol. 134 , no. Suppl. 1 , 5314 . https://doi.org/10.1182/blood-2019-129113

  9. 9
  10. 10
    Conference

    المصدر: Jørgensen , J , Leppä , S , Relander , T , Larsen , T S , Lauritzsen , G F , de Nully Brown , P , Mannisto , S , Minotti , G , Menna , P , Holte , H , Liestøl , K , Toldbod , H & D’Amore , F 2018 , ' A PHASE IB, OPEN LABEL, MULTICENTER TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20-POSITIVE TUMORS, RITUXIMAB (PREBEN) IN RELAPSED AGGRESSIVE LYMPHOMAS OF B- OR T-CELL PHENOTYPE ' , EHA Learning Center , vol. 2018 , PB1767 . < https://learningcenter.ehaweb.org/eha/2018/stockholm/216625/f.d.amore.a.phase.ib.open.label.multicenter.trial.of.pixantrone.etoposide.html?f=menu=14*media=3*speaker=92563*browseby=8 >

  11. 11
    Conference

    المصدر: d'Amore , F , Leppa , S , da Silva , M G , Relander , T , Lauritzsen , G F , Brown , P D N , Pezzutto , A , Doorduijn , J K , Weidmann , E , van Gelder , M , Van Hoof , A , Christiansen , I , Fagerli , U M , Hagberg , H , Lugtenburg , P J , Walewski , J , Wu , K L , Demuynck , H M , Fijnheer , R , Christensen , J H , Jankovska , M , Josefsson , ....

  12. 12
    Book
  13. 13
    Book

    المصدر: D'Amore , F A , Relander , T , Lauritzen , G F , Jantunen , E , Mannisto , S , Meyer , P , Ellin , F , Pedersen , M B & Toldbod , H 2016 , Hematopoietic stem-cell transplantation in peripheral T-cell lymphomas . in Hematopoietic cell transplants - Concepts, controversies and future directions . Cambridge University Press .

  14. 14
    Electronic Resource

    المصدر: Jerkeman , M , Eskelund , C W , Hutchings , M , Räty , R , Wader , K F , Laurell , A , Toldbod , H , Pedersen , L B , Niemann , C U , Dahl , C , Kuitunen , H , Geisler , C H , Grønbæk , K & Kolstad , A 2018 , ' Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON) : a multicentre, open-label, single-arm, phase 2 trial ' , The Lancet Haematology , vol. 5 , no. 3 , pp. e109-e116 .

    مصطلحات الفهرس: article

  15. 15
  16. 16
    Conference

    المصدر: D'Amore , F A , Jørgensen , J M , Sillesen , I B , Segel , E , Bentzen , H H N , Thorsgaard , M , Pulcynski , E , Pedersen , B , Gillstrom , D , Clausen , M R , Kamper , P , Silkjær , T , Gormsen , L C , Leppä , S & Toldbod , H 2014 , ' Preliminary clinical experience on the efficacy and feasibility of a new combination regimen consisting of pixantrone, etoposide and bendamustine with or without the addition of rituximab in patients with relapsed/refractory ....

  17. 17
    Conference

    المصدر: D'Amore , F A , Lauritzsen , G F , Relander , T , Jantunen , E , Hagberg , H , Anderson , H , Holte , H , Osterborg , A , Merup , M , Brown , P , Kuittinen , O , Erlanson , M , Ostenstad , B , Fagerli , U , Gadeberg , O , Sundstrom , C , Delabie , J , Ralfkiaer , E , Vornanen , M & Toldbod , H 2013 , ' Late relapses in peripheral T-cell lymphoma patients treated in the nordic NLG-T-01 trial ' , ....

  18. 18
    Conference
  19. 19
    Conference

    المصدر: Lauritzsen , GF , Gomes da Silva , M , Leppa , S , Pezzutto , A , Relander , T , Weidmann , E , van Gelder , M , Doorduijn , J , Hansen , PB , Altmann , B , Toldbod , H & D'Amore , F A 2011 , ' Alemtuzumab does not affect hematopoietic recovery after autologous stem cell transplantation in T-cell lymphoma: Data from the ACT-1 trial ' , Annals of Oncology , vol. 22 , no. 4 , pp. 476 .

  20. 20
    Conference